Clinical Trials
IPX203 provides more relief in fewer daily doses for Parkinson’s with motor fluctuations
An oral, extended-release therapeutic provided more ‘good’ on-time in fewer daily doses compared with immediate-release carbidopa/levodopa in Parkinson’s disease with motor fluctuations, according to research presented in JAMA Neurology.
VIDEO: Longer term ofatumumab lessened disability progression in MS
Longer-term treatment with ofatumumab led to lessening of disability progression and slowing of brain volume loss, according to Jeffrey A. Cohen, MD, in this Healio video.
FDA grants orphan drug designation to Duchenne muscular dystrophy treatment
The FDA has granted orphan drug designation to Avidity Biosciences Inc. for AOC 1044, its investigational monoclonal antibody to treat Duchenne muscular dystrophy in those with mutations amenable to exon 44 skipping.
Denali Therapeutics announces discontinuation of Alzheimer’s drug trial
A Bay Area clinical research and development firm announced it will discontinue development of a novel therapeutic for Alzheimer’s disease.
VIDEO: Inebilizumab reduces plasma cell signature, B-cell intrusion in NMOSD attacks
Treatment with inebilizumab was effective in reducing two telltale signs of an attack of neuromyelitis optica spectrum disorder, Bruce A. Cree, MD, PhD, MAS, said in this Healio video.
Anti-amyloid drug shows significant immune response in adults with mild Alzheimer’s
Treatment with an investigational anti-amyloid therapeutic for adults with mild Alzheimer’s disease was safe, efficacious and demonstrated a significant immune response up to 78 weeks, per a study published in EBioMedicine.
Interventional stroke program not superior to standard care at 1 year
No differences in incidence of vascular events were observed in adults with ischemic stroke who received interventional care compared with standard care 1 year after baseline assessment, data show.
Results from nearly half of oncology trials unreported within 3 years of completion
A review of oncology trials showed approximately two-thirds did not report results on any of three key platforms within 1 year of completion.
Kesimpta lowered relapse, suppressed lesion activity in MS up to 5 years
For those with relapsing multiple sclerosis, continuous treatment with Kesimpta demonstrated sustained efficacy for annual relapse rates as well as significant suppression of MRI lesion activity for up to 5 years, according to research.
First patient dosed in phase 2 study of hypoxic ischemic encephalopathy drug
A Virginia-based biotech company has announced dosing of the first patient in a phase 2 clinical trial examining safety and efficacy of its investigational anti-inflammatory peptide, RLS-0071, to treat hypoxic ischemic encephalopathy in newborns.